Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 7.00% is in line with its 5-year average of 6.45%, around the middle of its 5-year range (0.10%–12.30%).
19.88% below its 12-month average of 8.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 12.30%.
EBITDA MARGIN
7.00%
EBITDA MARGIN AVG TTM
8.74%
EBITDA MARGIN AVG 3Y
6.35%
EBITDA MARGIN AVG 5Y
6.45%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-19.88%
CURRENT VS 3Y AVG
+10.31%
CURRENT VS 5Y AVG
+8.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.01B
EBITDA Margin
39.14%
TTM Avg
19.43%
3Y Avg
-11.55%
5Y Avg
-189.29%
Market Cap
$2.02B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.01B
EBITDA Margin
-111.53%
TTM Avg
-109.12%
3Y Avg
-103.85%
5Y Avg
-277.10%
Market Cap
$2.06B
EBITDA Margin
-512.27%
TTM Avg
-49559.94%
3Y Avg
-46888.38%
5Y Avg
-33454.98%
Market Cap
$2.07B
EBITDA Margin
-18934.67%
TTM Avg
-10834.15%
3Y Avg
-7159.00%
5Y Avg
-5150.48%
Market Cap
$1.98B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Progyny, Inc. (PGNY) | $2.03B | 7.00% | 8.74% | 6.35% | 6.45% |
| Vericel Corporation (VCEL)vs › | $2.05B | 8.11% | 6.17% | 0.86% | 0.69% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | 39.14% | 19.43% | -11.55% | -189.29% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 40.34% | 23.31% | -20.04% | -112.62% |
| UroGen Pharma Ltd. (URGN)vs › | $2.01B | -111.53% | -109.12% | -103.85% | -277.10% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -512.27% | -49559.94% | -46888.38% | -33454.98% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -18934.67% | -10834.15% | -7159.00% | -5150.48% |
| Alvotech (ALVO)vs › | $2.08B | 19.79% | 20.20% | -178.47% | -247.76% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 1.74% | -0.52% | 3.36% | 2.51% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 7.12% | 6.21% | -1.19% | -11.55% |
Gross Margin
24.6%
EBITDA Margin
7.0%
Operating Margin
8.6%
Net Margin
6.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 12.30% |
| 2026-03-31 | 11.22% |
| 2025-12-31 | 5.21% |
| 2025-09-30 | 7.27% |
| 2025-06-30 | 7.68% |
| 2025-03-31 | 7.80% |
| 2024-12-31 | 5.58% |
| 2024-09-30 | 4.64% |
| 2024-06-30 | 7.05% |
| 2024-03-31 | 6.92% |
| 2023-12-31 | 5.35% |
| 2023-09-30 | 6.68% |
| 2023-06-30 | 5.62% |
| 2023-03-31 | 6.02% |
| 2022-12-31 | 1.75% |
| 2022-09-30 | 5.68% |
| 2022-06-30 | 4.73% |
| 2022-03-31 | 0.18% |
| 2021-12-31 | 0.10% |
| 2021-09-30 | 7.63% |
| 2021-06-30 | 9.29% |
| 2021-03-31 | 10.01% |
| 2020-12-31 | 1.41% |
| 2020-09-30 | 5.35% |
| 2020-06-30 | -0.95% |
| 2020-03-31 | 4.88% |
| 2019-12-31 | 2.58% |
| 2019-09-30 | 5.89% |
| 2019-06-30 | 5.17% |
| 2019-03-31 | 7.67% |
| 2018-12-31 | -0.74% |
| 2018-09-30 | -0.41% |
| 2018-06-30 | 0.60% |
| 2018-03-31 | -6.28% |
